Mitochondrial DNA D-loop in pancreatic cancer: Somatic mutations are epiphenomena while the germline 16519T variant worsens metabolism and outcome

American Journal of Clinical Pathology

Volumn 126, Issue 4, 2006, Pages 593-601

  Navaglia, Filippo ^a   Basso, Daniela ^a   Fogar, Paola ^a   Sperti, Cosimo ^a   Greco, Eliana ^a   Zambon, Carlo Federico ^a   Stranges, Alessia ^a   Falda, Alessandra ^a   Pizzi, Sara ^a   Parenti, Anna ^a   Pedrazzoli, Sergio ^a,b   Plebani, Mario ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

Chronic pancreatitis; Diabetes mellitus; Mitochondrial DNA; Pancreatic neoplasms

Indexed keywords

MITOCHONDRIAL DNA;

ADULT; AGED; ALLELE; ARTICLE; CANCER GRADING; CANCER STAGING; CHRONIC PANCREATITIS; CONTROLLED STUDY; DIABETES MELLITUS; DNA POLYMORPHISM; FEMALE; GENETIC PREDISPOSITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PANCREAS CANCER; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION;

EID: 33749353734     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/GQFCCJMH5KHNVX73     Document Type: Article

References (51)

1. Van Houten B, Woshner V, Santos JH. Role of mitochondrial DNA in toxic responses to oxidative stress. DNA Repair (Amst). 2006;5:145-152.
2. Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med. 2000;6:513-519.
3. Saelens X, Festjens N, Walle LV, et al. Toxic proteins released from mitochondria in cell death. Oncogene. 2004;23:2861-2874.
4. Green DR. Apoptotic pathways: ten minutes to dead. Cell. 2005;121:671-674.
5. Fernàndez-Silva P, Enriquez JA, Montoya J. Replication and transcription of mammalian mitochondrial DNA. Exp Physiol. 2003;88:41-56.
6. Penta JS, Johnson FM, Wachsman JT, et al. Mitochondrial DNA in human malignancy. Mutat Res. 2001;488:119-133.
7. Hochhauser D. Relevance of mitochondrial DNA in cancer. Lancet. 2000;356:181-182.
8. Carew JS, Huang P. Mitochondrial defects in cancer. Mol Cancer. 2002;1:9.
9. Birch-Machin MA. Using mitochondrial DNA as a biosensor of early cancer development [editorial]. Br J Cancer. 2005;93:271-272.
10. Jakupciak JP, Wang W, Markowitz ME, et al. Mitochondrial DNA as a cancer biomarker. J Mol Diagn. 2005;7:258-267.
11. Kang D, Hamasaki N. Alterations of mitochondrial DNA in common diseases and disease states: aging, neurodegeneration, heart failure, diabetes and cancer. Curr Med Chem. 2005;12:429-441.
12. Kose K, Hiyama T, Tanaka S, et al. Somatic mutations of mitochondrial DNA in digestive tract cancers. J Gastroenterol Hepatol. 2005;20:1679-1684.
13. Nishikawa M, Oshitani N, Matsumoto T, et al. Accumulation of mitochondrial DNA mutation with colorectal carcinogenesis in ulcerative colitis. Br J Cancer. 2005;93:331-337.
14. Petras JA, Baumann AK, Ruiz-Pesini E, et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proc Natl Acad Sci U S A. 2005;102:719-724.
15. Yoneyama H, Hara T, Kato Y, et al. Nucleotide sequence variation is frequent in the mitochondrial DNA displacement loop region of individual human tumor cells. Mol Cancer Res. 2005;3:14-20.
16. Tan D-J, Bai R-K, Wong L-JC. Comprehensive scanning of somatic mitochondrial DNA mutations in breast cancer. Cancer Res. 2002;62:972-976.
17. Miyazono F, Schneider PM, Metzger R, et al. Mutations in the mitochondrial DNA D-loop region occur frequently in adenocarcinoma in Barrett's esophagus. Oncogene. 2002;21:3780-3783.
18. Augenlicht LH, Heerdt BG. Mitochondria: integrators in tumorigenesis? Nat Genet. 2001;28:104-105.
19. Jones JB, Song JJ, Hempen PM, et al. Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res. 2001;61:1299-1304.
20. Basso D, Plebani M, Fogar P, et al. β-cell function in pancreatic adenocarcinoma. Pancreas. 1994;9:332-335.
21. Gullo L, Pezzilli R, Morselli-Labate AM, for the Italian Pancreatic Cancer Study Group. Diabetes and the risk of pancreatic cancer. N Engl J Med. 1994;331:81-84.
22. Basso D, Valerio A, Brigato L, et al. An unidentified pancreatic cancer cell product alters some intracellular pathways of glucose metabolism in isolated rat hepatocytes. Pancreas. 1997;15:132-138.
23. Ding X, Flatt PR, Permert J, et al. Pancreatic cancer cells selectively stimulate islet β cells to secrete amylin. Gastroenterology 1998;114:130-138.
24. Silverman DT. Risk factors for pancreatic cancer: a case-control study based on direct interviews. Teratog Carcinog Mutagen. 2001;21:7-25.
25. Basso D, Valerio A, Seraglia R, et al. Putative pancreatic cancer-associated diabetogenic factor: 2030 MW peptide. Pancreas. 2002;24:8-14.
26. Basso D, Millino C, Greco E, et al. Altered glucose metabolism and proteolysis in pancreatic cancer cell conditioned myoblasts: searching for a gene expression pattern with a microarray analysis of 5000 skeletal muscle genes. Gut. 2004;53:1159-1166.
27. Chari ST, Leibson CL, Rabe KG, et al. Probability of pancreatic cancer following diabetes: a population-based study. Gastroenterology. 2005;129:504-511.
28. Schernhammer ES, Hu FB, Giovannucci E, et al. Sugar-sweetened soft drink consumption and risk of pancreatic cancer in two prospective cohorts. Cancer Epidemiol Biomarkers Prev. 2005;14:2098-2105.
29. Chen Y, Liao WX, Roy AC, et al. Mitochondrial gene mutations in gestational diabetes mellitus. Diabetes Res Clin Pract. 2000;48:29-35.
30. Poulton J, Bednarz AL, Scott-Brown M, et al. The presence of a common mitochondrial DNA variant is associated with fasting insulin levels in Europeans in Auckland. Diabet Med. 2002;19:966-971.
31. Chinnery PF, Elliott HR, Patel S, et al. Role of the mitochondrial DNA 16184-16193 poly-C tract in type 2 diabetes. Lancet. 2005;366:1650-1651.
32. 't Hart LM, Hansen T, Rietveld I, et al. Evidence that the mitochondrial leucyl tRNA synthetase (LARS2) gene represents a novel type 2 diabetes susceptibility gene. Diabetes. 2005;54:1892-1895.
33. Maassen JA, Janssen GMC, 't Hart LM. Molecular mechanisms of mitochondrial diabetes (MIDD). Ann Med. 2005;37:213-221.
34. Sobin LH, Wittekind CL (International Union Against Cancer [IUCC]), eds. TNM Classification of Malignant Tumors. 6th ed. New York, NY: Wiley; 2002.
35. Resnick HE, Harris MI, Brock DB, et al. American Diabetes Association diabetes diagnostic criteria, advancing age, and cardiovascular disease risk profiles: results from the Third National Health and Nutrition Examination Survey. Diabetes Care. 2000;23:176-180.
36. Zhao Y-B, Yang H-Y, Zhang X-W, et al. Mutation in D-loop region of mitochondrial DNA in gastric cancer and its significance. World J Gastroenterol. 2005;11:3304-3306.
37. Wu C-W, Yin P-H, Hung W-Y, et al. Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer. Genes Chromosomes Cancer. 2005;44:19-28.
38. Habano W, Sugai T, Yoshida T, et al. Mitochondrial gene mutation, but not large-scale deletion, is a feature of colorectal carcinomas with mitochondrial microsatellite instability. Int J Cancer. 1999;83:625-629.
39. Lièvre A, Chapusot C, Bouvier A-M, et al. Clinical value of mitochondrial mutations in colorectal cancer. J Clin Oncol. 2005;23:3517-3525.
40. Wheelhouse NM, Lai PBS, Wigmore SJ, et al. Mitochondrial D-loop mutations and deletion profiles of cancerous and noncancerous liver tissue in hepatitis B virus-infected liver. Br J Cancer. 2005;92:1268-1272.
41. Salas A, Yao Y-G, Macaulay V, et al. A critical reassessment of the role of mitochondria in tumorigenesis. PLoS Med. 2005;2:1158-1166.
42. Garcea G, Dennison AR, Steward WP, et al. Role of inflammation in pancreatic carcinogenesis and the implications for future therapy. Pancreatology. 2005;5:514-529.
43. Maitra A, Cohen Y, Gillespie SED, et al. The human MitoChip: a high-throughput sequencing microarray for mitochondrial mutation detection. Genome Res. 2004;14:812-819.
44. Canter JA, Kallianpur AR, Pari FF, et al. Mitochondrial DNA G10398A polymorphism and invasive breast cancer in African-American women. Cancer Res. 2005;65:8028-8033.
45. Taylor RW, Turnbull DM. Mitochondrial DNA mutations in human disease. Nat Rev Genet. 2005;6:389-402.
46. Maassen JA, 't Hart LM, van Essen E, et al. Mitochondrial diabetes: molecular mechanisms and clinical presentation. Diabetes. 2004;53:S103-S109.
47. Weng S-W, Liou C-W, Lin T-K, et al. Association of mitochondrial deoxyribonucleic acid 16189 variant (T-C transition) with metabolic syndrome in Chinese adults. J Clin Endocrinol Metab. 2005;90(suppl 1):5037-5040.
48. Simmons RA, Suponitsky-Kroyter I, Selak MA. Progressive accumulation of mitochondrial DNA mutations and decline in mitochondrial function lead to β-cell failure. J Biol Chem. 2005;280:28785-28791.
49. Lin TK, Chen SD, Wang PW, et al. Increased oxidative damage with altered antioxidative status in type 2 diabetic patients harboring the 16189 T to C variant of mitochondrial DNA. Ann N Y Acad Sci. 2005;1042:64-69.
50. Selak MA, Armour SM, MacKenzie ED, et al. Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-α prolyl hydroxylase. Cancer Cell. 2005;7:77-85.
51. Gottlieb E, Armour SM, Harris MH, et al. Mitochondrial membrane potential regulates matrix configuration and cytochrome c release during apoptosis. Cell Death Differ. 2003;10:709-717.